ArticleClinical ophthalmology (Auckland, N.Z.)2020
Two-Year Multicenter Outcomes of iStent
Article in Clinical ophthalmology (Auckland, N.Z.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 34 citations in OpenAlex.
- A multicenter prospective comparative study evaluating cataract surgery and endoscopic cyclophotocoagulation either with or without iStent inject implantation in Brazilian patients with glaucoma.International ophthalmology · 2023Trial
- Clinical Outcomes of Trabecular Micro-Bypass Stent in Patients with Moderate-to-Severe Open-Angle Glaucoma.Korean journal of ophthalmology : KJO · 2026Article
- Trabecular Meshwork-Based MIGS: Efficacy, Technique Variability, and Wound Healing-A Comprehensive Review.Journal of clinical medicine · 2026Review
- From first generation to the next: evolution and research trends in iStent technology.Frontiers in medicine · 2025Review
- Visualization of the Postoperative Position of the HydrusJournal of clinical medicine · 2024Article
- Long-term efficacy and safety of XEN-45 gel stent implantation in patients with normal-tension glaucoma.BMC ophthalmology · 2024Article
- Comparison of Phacoemulsification Alone and With Trabecular Microbypass Stent in Primary Open-Angle Glaucoma and Normal-Tension Glaucoma: An 18-Month Outcome Study.Journal of ophthalmology · 2024Article
- Minimally Invasive Glaucoma Surgery: Safety of Individual Devices.Journal of clinical medicine · 2022Review
- Prospective 12-month outcomes of combined iStent inject implantation and phacoemulsification in Asian eyes with normal tension glaucoma.Eye and vision (London, England) · 2022Article
- Standalone Implantation of 2-3 Trabecular Micro-Bypass Stents (iStent inject ± iStent) as an Alternative to Trabeculectomy for Moderate-to-Severe Glaucoma.Ophthalmology and therapy · 2022Article
- Multicenter Effectiveness and Disease Stability Through 3 Years After iStentTrabecular Micro-Bypass with Phacoemulsification in Glaucoma and Ocular Hypertension.Clinical ophthalmology (Auckland, N.Z.) · 2022Article
- Two-Year Comparative Outcomes of First- and Second-Generation Trabecular Micro-Bypass Stents with Cataract Surgery.Clinical ophthalmology (Auckland, N.Z.) · 2021Article
- Treatment Success Across Different Levels of Preoperative Disease Burden: Stratified Two-Year Outcomes from the Pivotal Trial of iStentClinical ophthalmology (Auckland, N.Z.) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis multicenter study evaluated 2-year effectiveness and safety following implantation of two second-generation trabecular micro-bypass stents (iStent MATERIALS AND
methodsThis was a retrospective study of iStent
resultsA total of 340 eyes underwent surgery and had 24-month follow-up data. At 24 months, mean IOP decreased by 16% from 16.4±4.7 mmHg preoperatively to 13.7±3.1 mmHg (p<0.001), and 77% of eyes achieved IOP of ≤15 mmHg versus 49% preoperatively (p<0.001). Mean number of medications decreased by 67% to 0.49±0.95 versus 1.49±1.20 preoperatively (p<0.001), with 74% of eyes medication-free versus 25% preoperatively (p<0.001), and 14% of eyes on ≥2 medications versus 46% preoperatively (p<0.001). Medication burden was reduced or stable in 98% of eyes versus preoperative. Stratified analyses showed significant IOP and medication reductions across glaucoma subtypes (POAG, ACG, NTG, OHT): 13-22% for IOP (p<0.01 for all) and 62-100% for medication (p<0.001 for all). Favorable safety included few adverse events; stable CDR, VF, and visual acuity; and filtering surgery in only 8 eyes (2.4%) over 2 years.
conclusionThis 340-eye multicenter dataset provides robust evidence of the safety and efficacy of iStent
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.